Tadalafil Tablet
Product Images NDC 68788-8445

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68788-8445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tablets 20mg (761dc0f8 2f65 4615 Ab49 A4bcffd40ce9 00)

Label for Tadalafil Tablets 20 mg, a human prescription drug oral tablet. The label shows the product name and strength prominently, includes storage instructions and warnings, and identifies Ajanta Pharma Inc. as the manufacturer. The label also has sections for lot, batch, expiration date, and barcode, with dual-language directions in English and Spanish. The labeler is Preferred Pharmaceuticals Inc.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The X-axis shows treatment duration in weeks, and the Y-axis shows change in IPSS score. Tadalafil produces a greater reduction over time compared to placebo, with a statistically significant difference at 12 weeks (p<0.01).*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs illustrating the difference in blood pressure (BP) measurements between tadalafil and placebo over time in hours. The graphs show standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP with values plotted up to 96 hours, indicating changes in BP difference (mmHg) during this period.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs displaying changes in systolic blood pressure (mmHg) over 24 hours post-dose. The top graph shows standing systolic blood pressure and the bottom graph shows supine systolic blood pressure, comparing Tadalafil 20 mg with doxazosin 8 mg against placebo with doxazosin 8 mg over time.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph depicting the change in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo in combination with doxazosin. The x-axis represents time after administration in hours, and the y-axis shows systolic blood pressure change. Four groups are plotted: 20 mg tadalafil at 08:00 with 8 mg doxazosin, placebo with 8 mg doxazosin, and the same two groups at 20:00 dosing times.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours). The graph compares three conditions: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration, showing concentration changes up to 120 hours.*

FDA Label Image

Figure5 (Tadalafil Figure5)

Line graph showing the change from baseline in IPSS total score over 12 weeks of treatment. The graph compares Tadalafil 5 mg and placebo groups, indicating a greater reduction in symptoms with Tadalafil over time. The x-axis represents treatment duration in weeks, and the y-axis shows score change.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo. The x-axis shows treatment duration in weeks, and the y-axis shows the change from baseline in IPSS score, with data points showing greater improvement for Tadalafil 5 mg compared to placebo.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph depicting least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows mean change from baseline ranging approximately from 0 to -7. The graph includes statistical significance annotations for differences between treatment groups at specific time points.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of Tadalafil, the active ingredient depicted with its molecular rings and functional groups clearly shown as part of the generic drug formulation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.